Alamar Biosciences Partners With Nightingale Health on 80,000-Sample UK Biobank Neurodegenerative Disease Study

PUBT · 1d ago
Alamar Biosciences Partners With Nightingale Health on 80,000-Sample UK Biobank Neurodegenerative Disease Study
  • Alamar Biosciences partnered with Nightingale Health to launch a UK Biobank study covering 80,000 blood samples for neurodegenerative disease research.
  • Nightingale's laboratories will use Alamar's NULISA platform to measure hundreds of protein biomarkers linked to early disease signals.
  • The study targets earlier detection, prevention and treatment of Alzheimer's, Parkinson's and other neurodegenerative conditions, including rare dementias.
  • Alzheimer's Research UK, LifeArc and other partners are funding the study, with completion expected by the end of 2027.
  • The full dataset will become available to approved researchers worldwide through the UK Biobank Research Analysis Platform upon completion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alamar Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800OMX_____CNEWS_EN_GNW9867724_en) on November 02, 2026, and is solely responsible for the information contained therein.